BSE See NSE See 49,099.99
-1,939.32 (-3.8%)


Shruti Jadhav / Article rating: 3.5

Dalal Street Investment Journal has always been a pioneer in adopting the best practices so that our readers not only read the journal, but act in a prudent manner to take some sound decisions. Keeping in mind our logo “Democratising wealth creation,” we are pleased to have ranked 100 best business schools of the country, keeping the authenticity and objective of our tagline, intact. 


Vishal Dolas / Article rating: No rating

While some of the institutes are really striving to become world class in all respects, there are a good number of institutes that are running on expired courses and inefficient methods. In this era of intense competition and numerous choices, it is essential to be informed and aware of the relevant institutes and courses on offer.

DSIJ Mindshare

Sun Pharma share price slips 2 per cent post settlement order by SEBI

Anthony Fernandes / Article rating: 4.3

The shares of the drug manufacturer, Sun Pharmaceutical Industries Ltd had initially touched its 52-week high during the early trade on Friday but soon, slipped by almost 2 per cent after Securities & Exchange Board of India (SEBI) issued an order for settling charges made by a whistleblower.  

Alembic Pharma subsidiary secures USFDA accelerated approval for its partnered asset, Umbralisib

Anthony Fernandes / Article rating: 5.0

Rhizen Pharmaceuticals, a clinical-stage oncology-focussed biopharmaceutical company and a wholly-owned subsidiary of Alembic Pharma announced that its novel next-generation PI3K-delta inhibitor, Umbralisib, which was licensed to TG Therapeutics, has secured USFDA accelerated approval.  

Biocon Biologics signs agreement to expand access of cancer biosimilars to over 30 countries

Anthony Fernandes / Article rating: 4.3

Biocon Biologics, a fully-integrated biosimilars company and a subsidiary of Biocon Limited announced that it has signed an agreement with Clinton Health Access Initiative to expand access to lifesaving cancer biosimilars in over 30 countries in Africa and Asia as a part of Cancer Access Partnership (CAP).